Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...

New Activin R-based medications can emerge as perfect solutions for balancing weight loss and muscle building, making a ...

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...

Topline data from Hengrui’s Phase II trial for its GLP-1/GIP product demonstrated a statistically significant mean weight loss of 22.8%.

Proponents of Ozempic microdosing claim you'll reap the drug's benefits with fewer side effects. But is taking small doses of GLP-1 agonists safe and effective for weight loss?

Kailera and partner Jiangsu Hengrui Pharmaceuticals linked the injectable GLP-1/GIP receptor dual agonist to 22.8% mean weight loss after 36 weeks. The data come from a phase 2 trial Hengrui ...

Ozempic, Wegovy or Mounjaro? The battle of the weight-loss injections - As drugs emerge as vital to the Government’s ...

Its active ingredient is semaglutide, a glucagon-like peptide-1 (GLP-1 ... says Rekha Kumar, chief medical officer at the medically-assisted weight loss program, Found, and practicing ...

BAGSVAERD, Denmark I January 17, 2025 I Novo Nordisk today announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is ...

SPONSORED – Losing weight is no longer about will power or self-control, but STL Medical Weight Loss shares how it’s about food addiction. Dr. Joseph Moleski owner of STL Medical Weight Loss ...

reduced body weight by up to approximately 20% at 1 year in patients with overweight or obesity without a weight loss plateau, according to a presentation. The health benefits of time-restricted ...

Vistagen has reported positive outcomes from the exploratory Phase IIA trial of PH284 for the treatment of cancer cachexia.